AbbVie Continues To Chase Gilead With New HCV Data
This article was originally published in Scrip
Executive Summary
AbbVie Inc.'s once-daily, ribavirin (RBV)-free, pan-genotypic regimen, ABT-493/ABT-530, achieved impressive results in a Phase II study of genotype 2/3 hepatitis C patients, but it still might not be enough to dethrone current market leader Gilead Sciences.